Table 2.
Immunofluorescence characteristics of the ICI-BP cohort—some of these samples were taken at different time points or at disease maximum.
| No | DIF | ssIIF(roof side) | FLBP180 | BP180 NC16A | BP230 | IgE (kU/l) | Blood eosinophilia (thousands/µl) |
|---|---|---|---|---|---|---|---|
| 1 | IgM + | IgG + | 11.21 | 148 | 92 | 1,063 | 0.55 |
| 2 | IgG +, C3 + | IgG + | 16.19 | 39 | 10 | 233 | 2.31 (BP) |
| 3 | IgG +, C3 + | IgG + | 86.23 | n | n | 141 | 0.85 (ICI) |
| 4 | IgG +, C3 + | IgG + | 47.15 | 118 | n | 141 | 3.41 (BP) |
| 5 | NA | IgG + | n | 25 | n | 335 | 0.32 |
| 6 | NA | IgG + | 26.88 | n | n | NA | 0.37 |
| 7 | NA | IgG + | 7.74 | 10 | 15 | 21 | 3.57 (ICI) |
| 8 | IgG +, C3 +, discrete IgM | IgG + | 105.79 | 15 | 2 | NA | 0.45 |
n, negative; ssIIF, split skin of indirect immunofluorescence; FLBP180, cutoff <4.64 U/ml; BP180, NC16A cutoff <9 U/ml; BP230, cutoff < 9 U/ml; IgE positive > 100 kU/l, blood eosinophilia cutoff > 0.44 thousands/µl.